Objective: To examine whether there are clinical features in Japanese patients with both neurodegenerative diseases and cancers. Methods: We analyzed the clinical characteristics of consecutive Japanese patients with neurodegenerative diseases during the past 5 years, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), dementia with Lewy bodies, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Results: Out of 292 patients, 39 patients had cancers, including a past history, as follows: ALS, n = 16; PD, n = 8; PSP, n = 7; CBD, n = 1, and MSA, n = 7. About 10% of patients with neurodegenerative diseases developed cancer after onset of the disease; about 30% of patients with ALS, PD, or PSP occurring with cancers died of cancer. Gastric cancer was most common before the onset of ALS (62.5%) but did not develop after the onset of ALS. Conversely, PD patients frequently developed gastric cancers after the onset of neurological signs (60.0%) in spite of no cancer before the onset of PD. The proportion of breast cancer in MSA (45.5%) was significantly higher than in other neurodegenerative diseases. Conclusion: ALS, PD, or MSA patients with cancer showed clinical characteristics unique to each neurodegenerative disease in Japan compared to other countries.

Keywords:
Amyotrophic lateral sclerosis, Parkinson’s disease, Progressive supranuclear palsy, Multiple system atrophy, Gastric cancer, Breast cancer
1.
Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T, Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012;42:139-147.
2.
Ministry of Health, Labour and Welfare, Japan: Number of recipient certificates issued for specific disease treatment in 2007 (in Japanese). http://www.mhlw.go.jp/toukei/saikin/hw/eisei/07/kekka6.html (accessed February 22, 2013).
3.
Ministry of Health, Labour and Welfare, Japan: Number of recipient certificates issued for specific disease treatment in 2011 (in Japanese). http://www.mhlw.go.jp/toukei/saikin/hw/eisei_houkoku/11/dl/kekka7.pdf (accessed February 22, 2013).
4.
Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y: Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011;124:182-187.
5.
Ikejima C, Hisanaga A, Meguro K, Yamada T, Ouma S, Kawamuro Y, Hyouki K, Nakashima K, Wada K, Yamada S, Watanabe I, Kakuma T, Aoyama Y, Mizukami K, Asada T: Multicentre population-based dementia prevalence survey in Japan: a preliminary report. Psychogeriatrics 2012;12:120-123.
6.
Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
7.
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
8.
McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
9.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
10.
Boeve BF, Lang AE, Litvan I: Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54:S15-S19.
11.
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
12.
Norris FH, Engel WK: Carcinomatous amyotrophic lateral sclerosis; in Brain L, Norris FH (eds): The Remote Effect of Cancer on the Nervous System. New York, Grune and Stratton, 1965, pp 24-34.
13.
Zisfein J, Caroscio JT: No association of amyotrophic lateral sclerosis with cancer. Mt Sinai J Med 1988;55:159-161.
14.
Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB: Motor neuron syndromes in cancer patients. Ann Neurol 1997;41:722-730.
15.
Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA: Nonfatal cancer preceding Parkinson's disease: a case-control study. Epidemiology 2002;13:157-164.
16.
Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, Williams MM, Kopan R, Behrens MI, Morris JC: Cancer linked to Alzheimer disease but not vascular dementia. Neurology 2010;74:106-112.
17.
Baade PD, Fritschi L, Freedman DM: Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients. Neuroepidemiology 2007;28:16-20.
18.
Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H: Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201-205.
19.
Inzelberg R, Jankovic J: Are Parkinson disease patients protected from some but not all cancers? Neurology 2007;69:1542-1550.
20.
Bajaj A, Driver JA, Schernhammer ES: Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
21.
Sun LM, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH: Analysis of Parkinson's disease and subsequent cancer risk in Taiwan: a nationwide population-based cohort study. Neuroepidemiology 2011;37:114-119.
22.
Kamo K, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T: Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol 2008;38:571-576.
23.
Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S: Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-1877.
24.
Vigliani MC, Polo P, Chiò A, Giometto B, Mazzini L, Schiffer D: Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis. J Neurol 2000;247:778-782.
25.
Kijima Y, Yoshinaka H, Higuchi I, Owaki T, Aikou T: A case of amyotrophic lateral sclerosis and breast cancer. Breast Cancer 2005;12:57-59.
26.
Hays AP, Naini A, He CZ, Mitsumoto H, Rowland LP: Sporadic amyotrophic lateral sclerosis and breast cancer: hyaline conglomerate inclusions lead to identification of SOD1 mutation. J Neurol Sci 2006;242:67-69.
27.
Kogashiwa Y, Oishi N, Yamauchi K, Kohno N: Advanced hypopharyngeal cancer with amyotrophic lateral sclerosis. Auris Nasus Larynx 2011;38:750-752.
28.
Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-573.
29.
Chang HC, Horng JT, Lin WC, Lai HW, Chang CW, Chen TA: Evaluation of the appropriate age range of colorectal cancer screening based on the changing epidemiology in the past 20 years in Taiwan. ISRN Gastroenterol 2012;2012:960867.
30.
Adams R, van Bogaert L, van der Eecken H: Striato-nigral degeneration. J Neuropathol Exp Neurol 1964;23:584-608.
31.
Quinn N, Barnard RO, Kelly RE: Cerebellar syndrome in myxoedema revisited: a published case with carcinomatosis and multiple system atrophy at necropsy. J Neurol Neurosurg Psychiatry 1992;55:616-618.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.